Home Biosimilar Antibodies Others Others Enfortumab (Anti-Nectin-4)
For research use only. Not for use in humans.

Enfortumab (Anti-Nectin-4)

Synonyms: null

Enfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD.

Enfortumab (Anti-Nectin-4)

Quality Control

Batch: Purity: 99% Protein concentration: 9.17mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Enfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD.

Product Details

CAS No. 1448664-46-7
Molecular Weight 145.44 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06764095 RECRUITING Drug: Enfortumab Vedotin Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8 Mayo Clinic 2025-01-08 PHASE4
NCT07232602 RECRUITING Drug: MK-3120|Drug: EV|Drug: Rescue Medication Bladder Cancer Merck Sharp & Dohme LLC 2026-02-09 PHASE1; PHASE2
NCT07663747 NOT_YET_RECRUITING Drug: Enfortumab Vedotin|Drug: Pembrolizumab Urothelial Bladder Cancer The Netherlands Cancer Institute 2026-09-01 PHASE2
NCT07346053 NOT_YET_RECRUITING Drug: enfortumab vedotin and pembrolizumab (EV/P) Advanced Bladder Cancer Guliz Ozgun 2026-05 PHASE3
NCT07720284 RECRUITING Drug: Dato-DXd|Drug: Rilvegostomig|Drug: Durvalumab|Drug: Ni High-risk Muscle Invasive Urothelial Carcinoma AstraZeneca 2026-07-16 PHASE3
NCT03547973 ACTIVE_NOT_RECRUITING Drug: Sacituzumab Govitecan-hziy|Drug: Pembrolizumab|Drug: C Metastatic Urothelial Cancer Gilead Sciences 2018-08-13 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-02-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.